Key factors
sym | PDSB |
exch | US |
MCap | 106.37M |
Beta | 1.715 |
EPS | -1.39 |
Div date | 0000-00-00 |
Yesterday
sym | PDSB |
exch | US |
close | 3.26 |
50 Day MA | 4.687 |
200 Day MA | 5.064 |
52 Week High | 10.27 |
52 Week Low | 2.68 |
Target Price | 14.4 |
Market Cap Mln | 106.37 |
Share statistics
Shares Outstanding | 36.67M |
Shares Float | 35.40M |
Percent Institutions | 22.95 |
PercentInsiders | 3.67 |
SharesShort | 6152.08K |
Short Ratio | 4.76 |
Shares Short Prior Month | 5507.12K |
Short Percent | 17.56 |
Income
EBITDA | -42.9M |
Diluted Eps TTM | -1.39 |
earning
EPS Estimate Current Quarter | -0.44 |
EPS Estimate Current Year | -1.48 |
EPS Estimate Next Quarter | -0.44 |
EPS Estimate Next Year | -1.61 |
Earnings Share | -1.39 |
Dividend
Dividend Date | 2019-03-18 |
Last Split Date | 2019-03-18 |
Last Split Factor | 1:20 |
business
Enterprise Value Ebitda | -2.09 |
Book Value /share | 0.79 |
Price Book MRQ | 4.470 |
ReturnOnAssetsTTM | -0.39 |
ReturnOnEquityTTM | -1.22 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US70465T1079 |
CIK | 1472091 |
Code | PDSB |
CUSIP | 70465T107 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 25.0 |
IPODate | 2015-10-01 |
MostRecent Quarter | 2023-12-31 |
Contact
Name | PDS Biotechnology Corp |
Address | 303A College Road East, Princeton, NJ, United States, 08540 |
Country Name | USA |
Phone | 800 208 3343 |
Web URL | https://www.pdsbiotech.com |
Logo URL | /img/logos/US/PDSB.png |
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.